Evodiamine inhibits growth of Huh7 cells and enhances their sensitivity to TRAIL

AIM: To investigate the effects of evodiamine on the growth and apoptosis of human hepatocellular carcinoma Huh7 cells, and to illustrate the molecular mechanism that evodiamine enhances antitumor activity of tumors necrosis factor-related apoptosis-inducing ligand (TRAIL) in Huh7 cells.METHODS: The cell viability was measured by MTT assay. The cell cycle distribution was analyzed by flow cytometry. The apoptosis rate was determined by TUNEL staining. The protein levels of cell cycle-and apoptosis-related proteins were detected by Western blot analysis.RESULTS: Treatment of Huh7 cells with evodiamine reduced the cell viability (P<0.05). Evodiamine induced cell cycle arrest in G₂/M phase by upregulation of p27, cyclin B1, cell division cycle protein 2 (Cdc2) and p-Cdc2. Evodiamine triggered apoptosis accompanied by cleavage of caspase-3 and poly(ADP-ribose) polymerase (PARP). Combination of evodiamine with TRAIL significantly reduced the cell viability and increased cleavage of caspase-3 and PARP as compared with the use of each agent alone. Moreover, evodiamine increased the expression of death receptor 5 (DR5) in the Huh7 cells.CONCLUSION: Evodiamine inhibits the cell growth by reducing the cell viability and inducing cell cycle arrest. Evodiamine also triggers cell apoptosis and enhances the sensitivity of Huh7 cells to TRAIL by upregulating the expression of DR5.